JP2020535131A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535131A5 JP2020535131A5 JP2020516514A JP2020516514A JP2020535131A5 JP 2020535131 A5 JP2020535131 A5 JP 2020535131A5 JP 2020516514 A JP2020516514 A JP 2020516514A JP 2020516514 A JP2020516514 A JP 2020516514A JP 2020535131 A5 JP2020535131 A5 JP 2020535131A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- neurotrophin
- hearing loss
- super
- superpartner
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 7
- 206010011878 Deafness Diseases 0.000 claims 6
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 6
- 208000016354 hearing loss disease Diseases 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 5
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 5
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 5
- 231100000888 hearing loss Toxicity 0.000 claims 5
- 230000010370 hearing loss Effects 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- 108090000742 Neurotrophin 3 Proteins 0.000 claims 3
- 102000004230 Neurotrophin 3 Human genes 0.000 claims 3
- 239000003900 neurotrophic factor Substances 0.000 claims 3
- 229940032018 neurotrophin 3 Drugs 0.000 claims 3
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims 2
- 206010011891 Deafness neurosensory Diseases 0.000 claims 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims 2
- 108090000099 Neurotrophin-4 Proteins 0.000 claims 2
- 102000003683 Neurotrophin-4 Human genes 0.000 claims 2
- 208000005141 Otitis Diseases 0.000 claims 2
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 claims 2
- 210000003477 cochlea Anatomy 0.000 claims 2
- 208000019258 ear infection Diseases 0.000 claims 2
- 229940097998 neurotrophin 4 Drugs 0.000 claims 2
- 231100000879 sensorineural hearing loss Toxicity 0.000 claims 2
- 208000023573 sensorineural hearing loss disease Diseases 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 206010011903 Deafness traumatic Diseases 0.000 claims 1
- 208000016621 Hearing disease Diseases 0.000 claims 1
- 206010020559 Hyperacusis Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 231100000895 deafness Toxicity 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000000959 ear middle Anatomy 0.000 claims 1
- 208000005457 endolymphatic hydrops Diseases 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940053128 nerve growth factor Drugs 0.000 claims 1
- 230000000508 neurotrophic effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023131227A JP2023154035A (ja) | 2017-09-20 | 2023-08-10 | 処置の方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017903828 | 2017-09-20 | ||
| AU2017903829 | 2017-09-20 | ||
| AU2017903829A AU2017903829A0 (en) | 2017-09-20 | Method of treatment | |
| AU2017903828A AU2017903828A0 (en) | 2017-09-20 | Improved supraparticles | |
| AU2018902513 | 2018-07-11 | ||
| AU2018902513A AU2018902513A0 (en) | 2018-07-11 | Improved supraparticles | |
| PCT/AU2018/051028 WO2019056061A1 (en) | 2017-09-20 | 2018-09-20 | PROCESSING METHOD |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023131227A Division JP2023154035A (ja) | 2017-09-20 | 2023-08-10 | 処置の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020535131A JP2020535131A (ja) | 2020-12-03 |
| JP2020535131A5 true JP2020535131A5 (https=) | 2021-11-11 |
Family
ID=65810122
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516514A Pending JP2020535131A (ja) | 2017-09-20 | 2018-09-20 | 処置の方法 |
| JP2020516508A Active JP7404231B2 (ja) | 2017-09-20 | 2018-09-20 | 改良された超粒子 |
| JP2023131227A Pending JP2023154035A (ja) | 2017-09-20 | 2023-08-10 | 処置の方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516508A Active JP7404231B2 (ja) | 2017-09-20 | 2018-09-20 | 改良された超粒子 |
| JP2023131227A Pending JP2023154035A (ja) | 2017-09-20 | 2023-08-10 | 処置の方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US20200253865A1 (https=) |
| EP (2) | EP3684342B1 (https=) |
| JP (3) | JP2020535131A (https=) |
| CN (2) | CN111278428A (https=) |
| AU (2) | AU2018337076B2 (https=) |
| ES (2) | ES2985193T3 (https=) |
| WO (2) | WO2019056062A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111278428A (zh) | 2017-09-20 | 2020-06-12 | 澳大利亚仿生研究所 | 治疗方法 |
| BR112020020930A2 (pt) * | 2018-04-11 | 2021-03-02 | Ohio State Innovation Foundation | composição de liberação de fármaco, método para tratar um distúrbio oftalmológico e kit |
| CN114040753A (zh) * | 2019-03-19 | 2022-02-11 | 澳大利亚仿生研究所 | 超粒子制剂 |
| CN110063968B (zh) * | 2019-04-18 | 2021-09-03 | 朗姿赛尔生物科技（广州）有限公司 | 一种特异性干细胞修复病变胰岛的方法 |
| US20230047254A1 (en) * | 2019-12-29 | 2023-02-16 | Gloriana Therapeutics | Mammalian Cells Secreting GDNF and Their Therapeutic Use |
| US20240278014A1 (en) * | 2021-06-24 | 2024-08-22 | Cochlear Limited | Methods and pharmaceutical formulations for modulating the properties of the blood labyrinth barrier |
| GB202213060D0 (en) * | 2022-09-07 | 2022-10-19 | Rinri Therapeutics Ltd | Surgical method for treatment of auditory disease or condition |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4468498A (en) | 1980-06-12 | 1984-08-28 | Rohm And Haas Company | Sequential heteropolymer dispersion and a particulate materal obtainable therefrom, useful in coating compositions as a thickening and/or opacifying agent |
| US5157084A (en) | 1990-10-12 | 1992-10-20 | The Dow Chemical Company | Process of making hollow polymer latex particles |
| US5521253A (en) | 1990-10-12 | 1996-05-28 | The Dow Chemical Company | Hollow polymer latex particles |
| SE9903958D0 (sv) | 1999-11-02 | 1999-11-02 | Boerje Sellergren | Porous materials for selective binding or transport of molecular guests |
| CA2583054A1 (en) | 2004-10-05 | 2006-04-13 | The University Of Melbourne | Porous polyelectrolyte materials |
| WO2009079688A1 (en) | 2007-12-21 | 2009-07-02 | The University Of Melbourne | Porous silica shell-mediated assembly of macromolecular capsules |
| CN102380102A (zh) * | 2011-11-02 | 2012-03-21 | 东华大学 | 一种环境响应性介孔硅纳米粒子的制备方法 |
| ES2657137T5 (en) * | 2012-03-28 | 2025-02-12 | Borealis Ag | Multimodal polymer |
| WO2014031676A1 (en) * | 2012-08-20 | 2014-02-27 | O-Ray Pharma, Inc. | Process for manufacturing drug delivery formulations |
| WO2015051364A1 (en) * | 2013-10-05 | 2015-04-09 | Omnova Solutions Inc | Supraparticles including hollow polymeric particles |
| US9534213B2 (en) * | 2014-03-04 | 2017-01-03 | The Regents Of The University Of Michigan | Spontaneously formed terminal supraparticles having nanoparticles for protein stabilization |
| CN104003404B (zh) * | 2014-05-19 | 2016-03-16 | 国家纳米科学中心 | 一种多孔二氧化硅纳米粒子的制备方法及其用途 |
| CN111278428A (zh) | 2017-09-20 | 2020-06-12 | 澳大利亚仿生研究所 | 治疗方法 |
-
2018
- 2018-09-20 CN CN201880069810.9A patent/CN111278428A/zh active Pending
- 2018-09-20 EP EP18857932.0A patent/EP3684342B1/en active Active
- 2018-09-20 ES ES18857932T patent/ES2985193T3/es active Active
- 2018-09-20 AU AU2018337076A patent/AU2018337076B2/en active Active
- 2018-09-20 WO PCT/AU2018/051029 patent/WO2019056062A1/en not_active Ceased
- 2018-09-20 EP EP18858164.9A patent/EP3684343B1/en active Active
- 2018-09-20 WO PCT/AU2018/051028 patent/WO2019056061A1/en not_active Ceased
- 2018-09-20 AU AU2018337668A patent/AU2018337668B2/en active Active
- 2018-09-20 JP JP2020516514A patent/JP2020535131A/ja active Pending
- 2018-09-20 CN CN201880068028.5A patent/CN111225663A/zh active Pending
- 2018-09-20 ES ES18858164T patent/ES2962580T3/es active Active
- 2018-09-20 JP JP2020516508A patent/JP7404231B2/ja active Active
- 2018-09-20 US US16/648,858 patent/US20200253865A1/en not_active Abandoned
-
2019
- 2019-07-01 US US16/459,263 patent/US11369661B2/en active Active
-
2022
- 2022-05-25 US US17/824,654 patent/US12048733B2/en active Active
- 2022-12-21 US US18/086,412 patent/US20230135903A1/en not_active Abandoned
-
2023
- 2023-08-10 JP JP2023131227A patent/JP2023154035A/ja active Pending
-
2025
- 2025-01-17 US US19/028,757 patent/US20250205308A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020535131A5 (https=) | ||
| Brummett et al. | Aminoglycoside-induced hearing loss in humans | |
| Green et al. | Complications following adult cochlear implantation: experience in Manchester | |
| Suga et al. | Labyrinthitis ossificans | |
| JP2020520956A5 (https=) | ||
| JP2023154035A (ja) | 処置の方法 | |
| Shea | Autoinflation treatment of serous otits media in children | |
| Hoshino et al. | Intralabyrinthine neurilemmoma: a histopathological report | |
| CN106852121B (zh) | 用于治疗神经感觉性听觉丧失的甾醇衍生物以及相应的组合物 | |
| JPH0584259A (ja) | 耳への薬理学的活性剤の拡張された送出装置及び方法 | |
| Okuno et al. | Temporal bone histopathologic findings in Alagille's syndrome | |
| KitamurA et al. | Cochlear hydrops in association with collapsed saccule and ductus reuniens | |
| ES2861674T3 (es) | Prótesis auditiva para el oído medio y método de recubrimiento relacionado | |
| CN100444816C (zh) | 乳突窦的通风管 | |
| US20170056447A1 (en) | Pharmaceutical Composition For Preventing Or Treating Sensorineural Hearing Loss Or Tinnitus Including Platelet-Rich Plasma And Method Using The Same | |
| RU2330638C2 (ru) | Способ мирингопластики помещением аутофасциального трансплантата снаружи на обнаженный фиброзный слой барабанной перепонки | |
| Halle-Rostock | SAVE THE DATE | |
| BRANCH IV | DEPARTMENT OF ENT MADURAI MEDICAL COLLEGE MADURAI, MAY 2020 | |
| Postma et al. | Polyethylene sponge total ossicular replacement prosthesis: A histopathologic study | |
| Michaels | Inner Ear | |
| RU2651110C1 (ru) | Способ хирургического лечения хронической вторичной сенсоневральной тугоухости | |
| Bruk | Development of a Novel Topical Controlled Release System for Otic Drug Delivery | |
| KR20220019764A (ko) | 내이로 물질을 전달하기 위한 방법 및 장치 | |
| Calon | The Bone Anchored Hearing System: Understanding and improving clinical outcomes | |
| Atlas, MD* & Lowinger | The GP's essential guide to hearing loss |